Pharma · Public company · North Chicago, IL, US
AbbVie Inc.
Ticker ABBV · SEC CIK 0001551152
Track this companyFree. Adds AbbVie Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs25From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline25
- Artificial TearsPhase 3 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Ranibizumab ControlPhase 3 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- RisankizumabPhase 3 · Psoriatic Arthritis (PsA)ClinicalTrials.gov · fetched Nov 12, 2026
- ShamPhase 3 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- Surabgene LomparvovecPhase 3 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- Surabgene Lomparvovec (ABBV-RGX-314)Phase 3 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Telisotuzumab VedotinPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Topical SteroidPhase 3 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- ABBV-547Phase 2 · Psoriatic ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- ABBV-701Phase 2 · Psoriatic ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- AfliberceptPhase 2 · Diabetic Retinopathy, DRClinicalTrials.gov · fetched Nov 12, 2026
- LutikizumabPhase 2 · Psoriatic ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- MEDI0618Phase 2 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
- OnabotulinumtoxinAPhase 2 · Upper Facial LinesClinicalTrials.gov · fetched Nov 12, 2026
- RisankizumabPhase 2 · Psoriatic ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- TrenibotulinumtoxinE and OnabotulinumtoxinAPhase 2 · Upper Facial LinesClinicalTrials.gov · fetched Nov 12, 2026
- ABBV-101Phase 1 · Hematologic CancerClinicalTrials.gov · fetched Nov 12, 2026
- ABBV-295Phase 1 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- ABBV-295Phase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
- ABBV-7828Phase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- AGN-151586Phase 1 · Glabellar LinesClinicalTrials.gov · fetched Nov 12, 2026
- BOTOXPhase 1 · Glabellar LinesClinicalTrials.gov · fetched Nov 12, 2026
- Etentamig (ABBV-383)Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- TrosunilimabPhase 1 · Healthy VolunteerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult ParticipantsPHASE1 · RECRUITING · started Oct 13, 2026ClinicalTrials.gov NCT07925983 · fetched Nov 12, 2026
- A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial LinesPHASE2 · RECRUITING · started Oct 8, 2026ClinicalTrials.gov NCT07871513 · fetched Nov 12, 2026
- A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy AdultsPHASE1 · RECRUITING · started Oct 2, 2026ClinicalTrials.gov NCT07856706 · fetched Nov 12, 2026
- Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaPHASE2 · RECRUITING · started Sep 16, 2026ClinicalTrials.gov NCT07734038 · fetched Nov 12, 2026
- A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar LinesPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 10, 2026ClinicalTrials.gov NCT07756580 · fetched Nov 12, 2026
- Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson DiseaseRECRUITING · started Aug 3, 2026ClinicalTrials.gov NCT07227896 · fetched Nov 12, 2026
- Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaPHASE2_PHASE3 · RECRUITING · started Jun 1, 2026ClinicalTrials.gov NCT07592273 · fetched Nov 12, 2026
- A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.PHASE1 · ACTIVE_NOT_RECRUITING · started Mar 31, 2026ClinicalTrials.gov NCT07514260 · fetched Nov 12, 2026
- A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With ObesityPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 19, 2025ClinicalTrials.gov NCT07291232 · fetched Nov 12, 2026
- A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)PHASE2 · RECRUITING · started Nov 11, 2025ClinicalTrials.gov NCT07231952 · fetched Nov 12, 2026
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)PHASE3 · RECRUITING · started Nov 5, 2025ClinicalTrials.gov NCT07007065 · fetched Nov 12, 2026
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPHASE2 · RECRUITING · started Apr 11, 2025ClinicalTrials.gov NCT06865105 · fetched Nov 12, 2026
- GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 30, 2025ClinicalTrials.gov NCT06522386 · fetched Nov 12, 2026
- A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigrainePHASE2 · ACTIVE_NOT_RECRUITING · started Oct 7, 2024ClinicalTrials.gov NCT06602479 · fetched Nov 12, 2026
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 9, 2023ClinicalTrials.gov NCT05753501 · fetched Nov 12, 2026
- A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple MyelomaPHASE1 · RECRUITING · started Mar 21, 2023ClinicalTrials.gov NCT05650632 · fetched Nov 12, 2026
- Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 1, 2022ClinicalTrials.gov NCT05183035 · fetched Nov 12, 2026
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 4, 2022ClinicalTrials.gov NCT05296447 · fetched Nov 12, 2026
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)PHASE3 · RECRUITING · started Mar 25, 2022ClinicalTrials.gov NCT04928846 · fetched Nov 12, 2026
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsPHASE1_PHASE2 · RECRUITING · started Feb 4, 2022ClinicalTrials.gov NCT04797767 · fetched Nov 12, 2026
- A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 13, 2021ClinicalTrials.gov NCT04628494 · fetched Nov 12, 2026
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 25, 2020ClinicalTrials.gov NCT04623541 · fetched Nov 12, 2026
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 3, 2020ClinicalTrials.gov NCT04663347 · fetched Nov 12, 2026
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 7, 2019ClinicalTrials.gov NCT03671148 · fetched Nov 12, 2026
- First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 26, 2018ClinicalTrials.gov NCT03625037 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 30, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 3, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 18, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026